Agenda for the 10th Nobel Linus Pauling Symposium
Sat, Sept 2, 2006 Convention Hall 2, 1/F., Core Building, HKSP, 10 am to 5 pm 9:30 - 10:00 am Registration, Networking 10:00 am Welcome: Dr. Bernard Chan (Director, LifeTech)
Dr. Grace Wong, CSO, ActoKine Therapeutics (Boston)To build a bridge between USA and Hong Kong-China
Keynote: Mr. Carlos Genardini, CEO, HKSP
Raffle drawing by Mr. Carlos Genardini (3 Prizes)
Keynote: Dr. John Lo, Sr. Advisor, HKSP
Q&A for all 3 speakers11:30 am Dr. Grace Wong, President of Student Vision (Boston)
Get a foot in the door: USA biotech & pharma companies
Biotech who's who: smart pitch or self introduction.12:00 - 1:00pm Lunch Buffet & Neworking at CyberCafe, G/F., Core Building, HKSP 1:00 - 2:00 pm Moderator: Dr. Benjamin Lee, Comprehensive Drug Enterprises
Mr. Kevin Zhou, CEO, Sino-Swed TongKang Biological Tech (SSTK), Shenzhen
Dr. Xian-Ping Lu, CEO of ChipScreen from Shenzhen
Dr. Yaozhou Shi, BioChip, Shanghai
Dr. Andy Chiu, Deputy Director, HKJCICM
Dr. Bing Wong, CEO, Advantek Biologics
Q&A for all speakers (10 min)2:00 - 2:30 pm Networking 2:30 - 3: 30 pm Moderator: Dr. Eric Xing, CK Life Sciences
Dr. Steven Hardacre, Managing Director, Merck HK (also President of API)
Dr. Terence Lau, COO, HKDNA Chip
Dr. Bjorn Hammarberg, Managing Director, ABD Life Sciences
Professor Moses Chow, Director of Drug Development Center, CUHK
Dr. Zhongyuan Zhu, Senior Director, Shanghai Genomics
Q&A for all speaker (10 min)4:00 - 5:00 pm Panel discussion: All speakers from Academia, Biotech and Pharma companies.
Doing R & D Globally: West meets East
Moderators: Dr. Albert Wong, Zigen Pharmaceuticals, Dr. Edmund Lee, CEO, HKJCICM
Raffle Drawing (3 prizes)5:00 - 6:00 pm Networking
Carlos GenardiniMr. Carlos Genardini CEO, Hong Kong Science Park
Mr. Genardini is the CEO of Hong Kong Science Park. Mr. Genardini brings over two decades of technology management and experience to the role of CEO including four years as a vice president and manager of Motorola's Asia Pacific Group. During this time, Mr. Genardini became involved in developing the semiconductor and technology industries in Hong Kong and throughout the region. Mr. Genardini has set up and managed state-of-the-art chip design facilities in Hong Kong, Singapore and China, sat on the committees of engineering departments in the University of Hong Kong and the City University of Hong Kong, and was a founding Board member of the Provisional Hong Kong Science Park Company Ltd., which later merged into the present Hong Kong Science and Technology Parks Corporation. Mr. Genardini has a track record as an experienced executive of a major multinational corporation, knowledge of global and regional technology industries, an extensive network of contacts, and commitment and enthusiasm in helping to promote and further develop the Science Park. He is a member of the Board of the Provisional Hong Kong Science Park Company Ltd. that began the Science Park, and was the founder and CEO of Genardini & Associates, a strategic business consultancy providing market research and support along with special development work for companies looking to business in China. Prior to that Mr. Genardini was Motorola's president for Latin America and the Caribbean.
Dr. John S.K. LoDr. John S.K. Lo Senior Advisor to CEO, Hong Kong Science Park
Dr. John S.K. Lo, OBE, and JP is the Senior Advisor to CEO, the Hong Kong Science and Technology Parks Corporation. He is also a Director of several private sector companies in Hong Kong and China. He has over 30 years of senior management experience in various marketing and manufacturing fields in Asia, ranging from consumer, industrial to aerospace military specification products manufacturing. His working experience covered Australia, Singapore, Malaysia, Taiwan, Hong Kong, United Kingdom, Europe, U.S.A., Japan, China, Indonesia and Vietnam. His work requires him to travel extensively in these regions. He is also the Honorary Chairman of the Hong Kong Quality Assurance Agency, the Honorary Chairman of the Hong Kong Standards & Testing Center Ltd. and he was an active member of several important government appointed committees.
Dr. Bing WongDr. Bing Wong CEO, Advantek Biologics
Dr. Bing Wong, CEO of Advantek Biologics. Dr. Wong is also Chairman of C & B Corporation, Hong Kong, distributor of Biopure Oxyglobin and Hemopure in the Asian Pacific and Chairman of API, Inc, of New Jersey, USA, an active pharmaceutical ingredient contract manufacturer. In August 2006, Dr. Wong was appointed as an adjunct professor of the Chinese university of Hong Kong. Dr. Wong holds a B.S. in Chemical Engineering from the National Taiwan University, and M.S. and Ph.D. degrees in Chemical Engineering from Tufts University. Prior to joining Advantek, Dr. Wong was a founder and Senior Vice President of Biopure Corporation in Cambridge, Massachusetts. He has also been an Association Professor in Chemical Engineering and Acting Director of the New England Enzyme Center at Tufts Medical School. Dr. Wong holds many patents in Biomedicine, including artificial blood replacements and antibiotics. He has served as Chairman of the Chinese Economic Development Council, Inc., a community service organization in Boston’s Chinatown. CEDC assists local residents for job training, enhances local economic development, as well as establishing numerous of moderate and low-income housing projects and education program for local residents. In 1992, Dr. Wong was named "A Model of Overseas Chinese Young Entrepreneur" by the Executive Yuan, Taiwan, Republic of China. In 2001, Bunker Hill Community College of Boston, Massachusetts awarded him the President Distinguished Service Award for his extraordinary commitment for higher education in the Boston Asian community.
Albert C. H. YuAlbert C. H. Yu CEO, HKDNA Chips
Professor Albert C. H. Yu is the founder, Chairman and Chief Executive Officer of HKDNA Chips. He is a well-known scientific conference organizer, neuroscientist and biotechnology entrepreneur, active in numerous cross-cultural and industrial communities in Hong Kong and China. With a global network and an expanding base of established contacts in China, Prof. Yu has been an important facilitator of dialogue regarding the development of biotechnology in Asia. Prof. Yu is currently a professor at the Neuroscience Research Institute and Department of Neurobiology at Peking University, China. After receiving his BSc, MSc and PhD from the University of Saskatchewan, Canada, Prof. Yu moved to the University of California at San Francisco and subsequently spent four years at Stanford University and was honored with the status of Visiting Associate Professor. He also spent time as an investigator at the NASA Ames Research Center. Upon returning to Hong Kong, he joined the Hong Kong University of Science and Technology as a faculty member. He was a guest professor at the Shanghai Jiao Tong University, visiting professor at The First Military Medical University, and visiting investigator at the Chinese Academy of Sciences. Over his academic and research career, Prof. Yu has published 3 books and over 200 peer-reviewed scientific articles and conference papers. He is also the co-inventor of numerous technologies with 6 patents granted and others pending
Dr. Xianping LuDr. Xianping Lu President & Chief Scientific Officer, Shenzhen Chipscreen Biosciences Ltd
Dr. Xianping Lu is currently Member of the board of Directors, President, and Chief Scientific Officer of Shenzhen Chipscreen Biosciences Ltd, the leading drug discovery company in China. Dr. Lu also serves in several Advisory Committees for Biotech/Pharma/Life Sciences Division of different levels of Governments in China. Dr. Lu finished his B.S. degree in Biochemistry from University of Sichuan in 1983. He obtained respectively M.S. in Biochemistry and Ph.D. in Molecular Biology in 1986 and 1988 from Peking Union Medical College and Chinese Academy of Medical Sciences. Dr. LU completed his Postgraduate Pharmacologist Fellowship study at the Department of Pharmacology, School of Medicine, University of California at San Diego between 1989 and 1992. He continued his postdoctoral research at La Jolla Cancer Research Foundation (Burham Institute) prior to participate in founding Galderma Research Inc. and Maxia Pharmaceuticals in San Diego in 1995. He was the Director of Research at Galderma R & D (a subsidiary of L'Oreal and Nestle) in Princeton till 2000. He became visiting professor at The State Key Laboratory for Biomembrane and Membrane Biotechnology in Tsinghua University in the same year. During this period, he has led a group of US-trained talented scientists to successfully found Chipscreen Biosciences Ltd. in Shenzhen. Dr. Lu has more than 20 years biomedical research and biotech/pharmaceutical experiences in varieties of therapeutic area. He is a skilled leader of diverse groups within a global operating environment. During his career, he has published many research papers in journals such as Nature, Science, and Nature Medicine. He is the co-inventor of many inventions in area of small molecule therapeutics.
Moses ChowMoses Chow Professor, Chinese University of Hong Kong
Professor Moses Chow is the Director of the Drug Development Centre, Professor and Director of the School of Pharmacy of the Faculty of Medicine, the Chinese University of Hong Kong. He received his Doctor of Pharmacy degree from the University of California, San Francisco. He started his teaching and scientific career at the School of Pharmacy, the University of Connecticut. At about the same period, he was named fellow at the American College of Clinical Pharmacy and American College of Clinical Pharmacology. He held a number of academic, clinical, and administrative appointments, including president of the Asian Association of Schools of Pharmacy, Honorary Director of Collaborative Research at the Department of Pharmacy of the Hartford Hospital, member of Drug Utilization Review Committee of the Hospital Authority, member of Expert Advisory Panel on Cadiovascular and Renal Drugs for the United States Pharmacopeial Convention Inc., and member of Clinical Trials Review Committee of the U.S. National Heart, Lung and Blood Institute. Professor Chow has been member in a number of professional societies, like Drug Metabolism Section of the China Association for Science & Technology, Chinese Pharmacologic Society.
Dr. HammarbergDr. Hammarberg Managing Director, ABD Life Sciences Ltd
Dr. Hammarberg is the Managing Director and founder of ABD Life Sciences Ltd and the Virtual Bio-service Companies, with 20 years of global experiences in R&D, Marketing & Sales and Business Development of Life Sciences, spanning a wide variety of areas such as Molecular Biology, Biochemistry, Bioprocess, Medical Devices, Virus Removal / Inactivation, Biopharma facilities, performing global deal making acquiring and licensing in Key technologies, strategy development and implementation in Asia. Sales & Marketing of turn-key biopharma facilities including Lay-Out, Design, Engineering, Commissioning & Validation. Holistic problem solving in multi-culture environments as one specialty. On and off 15 years business experience in Asia.
Dr. Andrew ChiuDr. Andrew Chiu Deputy Director, Hong Kong Jockey Club Institute of Chinese Medicine
Dr. Andrew Chiu is the Deputy Director for Scientific Planning and Project Management for the Hong Kong Jockey Club Institute of Chinese Medicine. Dr. Chiu received his Ph.D. in Pharmacology from the University of Virginia. He began his career in academic research, moving into the pharmaceutical industry where he working in cardiovascular research, rising to Head of Discovery at Dupont Merck. Dr. Chiu was recruited into the biotechnology industry to manage and lead R&D for a variety of diagnostic and clinical projects. Dr. Chiu then moved into research on applications of Chinese medicine in neutraceuticals, managing R&D activities for Pharmanex/NuSkin, an international developer of neutraceuticals. He joined the HKJCICM in 2005. Dr. Chiu has published over 200 articles, 8 book chapters and holds 7 patents. He has been recognized as one of the Highly Cited Scientists in the world of technologies for the research on Cozaar® and Angiotensin receptors.
Steven E. HardacreSteven E. Hardacre Managing Director, Merck Sharp & Dohme
Steven E. Hardacre is the Managing Director of Merck Sharp & Dohme in Hong Kong and the current president of The Hong Kong Association of the Pharmaceutical Association (HKAPI). He has lived and/or worked in Asia for most of the last 28 years, including 13 years in Japan. He has more than 20 years experience in the pharmaceutical industry and a strong commitment to making innovative medicines universally. available
Grace Wong, PhDGrace Wong PhD, Founder & CSO of ActoKine Therapeutics, Founder of Student Vision
Dr. Grace Wong has worked for Genentech, Millennium, AstraZeneca and Serono on new drug discovery in a variety of therapeutic areas. Dr. Wong did a PhD at WEHI in Australia. In the US, Dr. Wong did a postdoc with Dr. David Goeddel at Genentech and she advanced basic research discoveries to product development in 1993. In 1996, Dr. Wong became the Head of Apoptosis Research at Millennium Pharma. In 1998, she joined AstraZeneca as Section Head of Molecular Genetics and identified potential genes for Alzheimer's disease. Since AstraZeneca was moving to Delaware, Dr. Wong joined Serono as Head of Functional Genomics. She has been awarded 13 scholarships and received 5 Recognition Awards from Genentech. She was invited to present at 139 international conferences including the Nobel Symposium (Sweden, 1994). She has published 87 papers and filed 27 patents (11 issued). Seven of her publications (3 Nature, 1 Science, and 3 Cell) received 500-900 citations. In 2003, Dr. Wong has founded Actokine Therapeutics (www.actokine.com) for drug advancements for biodefense projects (radioprotection against dirty bomb and protection against a broad spectrum of virus). She has also founded Student Vision for helping students of all ages in biotech science (www.studentvision.org).
Dr. Edmund T. Y. LeeDr. Edmund T. Y. Lee Executive Director, Hong Kong Jockey Club Institute of Chinese Medicine
Dr. Edmund T. Y. Lee, PhD. MBA. MIoD. FRSA. FIBiol. FCMI. Executive Director of the Hong Kong Jockey Club Institute of Chinese Medicine (HKJCICM) since 2001 - Dr Lee received his B.Sc and Ph.D in Microbiology at King's College, University of London. He also holds an MBA from the Warwick Business School and a Postgraduate Certificate in Chinese Medicine from the SPACE program of the University of Hong Kong. Prior to returning to Hong Kong, Dr Lee was Group Manager at Medeva Pharma (acquired by Celltech) and formerly, Group Leader at British Biotech Pharmaceuticals (now Vernalis). In late-1999, Dr Lee joined the new Innovation and Technology Commission (formerly the Industry Department) of the Hong Kong Special Administrative Region Government as Senior Biotechnology Officer advising the Commissioner on biotechnology and Chinese medicine development policy. He also served as Secretary of the Biotechnology and Environment Projects Vetting Committees. Currently, he is a member of the Chinese Medicine Working Party of the Mainland-Hong Kong Technology Collaboration Committee and the Chinese Medicine Research Committee of the Hospital Authority. Fellowships include Royal Society of Arts, Institute of Biology and the Chartered Management Institute in the UK, and the Biotechnology Industry Association in HK. Dr Lee is also a member of the Institute of Director.
Michael YangMichael Yang Professor, City University of Hong Kong
Professor Michael Yang obtained his BSc from Xiamen University, China (1984), MSc from Simon Fraser University, Canada (1989), and PhD from University of Toronto, Canada (1993). He obtained his postdoctoral training in Molecular Biology in The Scripps Research Institute, USA (1993-1994). He joined City University of Hong Kong in 1994 and is currently a full professor in Department of Biology and Chemistry and the Director of the Applied Research Centre for Genomics Technology. Professor Yang has received over $50 million research grants from external funding agencies and has trained 8 Ph.D. and 4 M.Phil. graduates since 1995. He has published over 100 peer-reviewed scientific papers on the development of novel analytical techniques for biomedical applications and on the studies of biomolecular interactions in cellular processes. His work has been recognized by awards in the Eurasia Chemical Conference (1996) and the Asia-Pacific Conference of Tumor Biology (2001). Professor Yang has been invited to deliver more than 50 lectures in international conferences and many universities and was awarded the K. C. Wong Education Foundation Scholar Award in 2003. He serves in the International Advisory Committee of “The Analyst” (Royal Society of Chemistry) and the Editorial Board of “Life Science Instruments” (Chinese Society of Chemistry). He holds honorary professorships in the University of Hong Kong, Zhejiang University, and The Third Military Medical University, China, and was a “Ministry of Education” senior visiting professor in Tsinghua University in 2003. Professor Yang is also a co-founder and director of Genetel Pharmaceuticals Ltd., a company specializing in developing molecular diagnostic and therapeutic products for early detection and treatment of diseases.
Dr. Terence L.T. LauDr. Terence L.T. Lau Executive Director and COO, HKDNA Chips Ltd
Dr. Terence L.T. Lau is the Executive Director and COO of HKDNA Chips Ltd and oversees day-to-day operations and business development of the company to maintain our commitment to excellence. As a co-inventor of HKDNA technologies, Dr. Lau is also responsible for scientific research, product commercialization and technology development of the company. Since 1997, he has been the founding member and key executive of two Hong Kong biotechnology companies specializing in DNA-related products and services and has developed and executed a number of biotechnology projects. Dr. Lau holds a B.Sc. (Hons) in Animal and Plant Biotechnology from the University of Hong Kong, an M.Phil. in Biology from the Hong Kong University of Science and Technology and a Ph.D. in Physiology from Peking University, China. Dr. Lau has a Diploma in Marketing from the Hong Kong Institute of Marketing and a wealth of strategic business experience he gained as a member of a multinational company's international marketing team. Dr. Lau's professional, firsthand knowledge in the diagnostic market and well-established connections in the medical industry has attracted frequent consultation from the industry and the media. He has also co-authored numerous publications in peer-reviewed scientific journals in the field of neuroscience and molecular biology.
Home | Mission | Registration | Sponsors | Job Strategies | News, Events, Contact
Biotech Booth | Event Photos | Nobel Day | Dr. Linus Pauling | Who's Who
Pauling Biotech Symposium | Symposium Agenda | Symposium Speakers | Symposium Testimonials
Founder & Board of Directors | Scientific Advisory Committee | Scholarship Application
copyright 2006
